{"disease":{"id":"vasomotor-symptoms-due-to-menopause","name":"Vasomotor symptoms due to menopause","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"elinzanetant","indication_name":"Moderate to severe vasomotor symptoms due to menopause","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ELINZANETANT","company_name":"","drug_phase":"marketed","molecular_target":"NK1, NK3","drug_class":"","quality_score":55,"revenue":null,"mechanism":"LYNKUET blocks NK1 and NK3 receptors, reducing Substance P and Neurokinin B signaling to modulate neuronal activity in thermoregulation."},{"drug_id":"fezolinetant","indication_name":"Vasomotor symptoms due to menopause","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Veozah","generic_name":"FEZOLINETANT","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Neuromedin-K receptor","drug_class":"Neurokinin 3 Receptor Antagonist [EPC]","quality_score":62,"revenue":null,"mechanism":"Veozah works by binding to the Neuromedin-K receptor, which helps to alleviate vasomotor symptoms."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}